GlaxoSmithKline

مادة اعلانية

Latest Update: 23 Apr 2025 16:28 Abu Dhabi Time.

Market Status: Closed

BIOC

GlaxoSmithKline

38.13

EGP

0.680

1.82%

Open

37.45

Prev Close

37.45

PX_VOLUME

85,014

MARKET CAP (M)

DAY RANGE

37.47 - 38.80

52 WEEKS

24.70 - 47.30

Stock Statistics

Yearly Change

20.82%

Listed Shares (Million)

83.51

Earnings Multiple

18.30

Average 30-day trading volume

71,089.29

Price-to-book ratio

1.60

Earnings Per Share

2.08

Previous Dividend Distribution

0.71

Dividend Yield

1.97%

Financial Summary

Quarterly
Annual

Income Statements

	Period Ending:	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023
Total Revenue		847.49	787.08	642.45	713.81	663.47	576.44
Gross Profit		271.80	175.96	330.14	326.35	459.45	170.45
Operating Income		129.25	81.65	132.86	76.32	291.41	105.17
Profit Margin		8.04	1.69	15.81	-1.26	2.07	4.71

	Period Ending:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Revenue		2,990.82	2,240.22	1,817.67	1,014.99	1,992.83
Gross Profit		1,104.25	843.33	572.53	307.04	779.84
Operating Income		420.08	440.90	18.94	11.49	202.51
Profit Margin		5.82	2.70	-6.26	-6.74	1.41

Balance Sheet

	Period Ending:	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023
Total Assets		3,652.63	3,712.12	3,744.61	3,971.75	3,557.92	3,557.41
Total Liabilities		1,657.08	1,784.72	1,830.48	2,089.49	1,592.59	1,605.81
Total Equity		1,995.56	1,927.40	1,914.13	1,882.26	1,965.33	1,951.60

	Period Ending:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Assets		3,652.63	3,557.92	3,185.07	2,424.75	2,117.34
Total Liabilities		1,657.08	1,592.59	1,456.63	1,066.79	904.25
Total Equity		1,995.56	1,965.33	1,728.43	1,357.96	1,213.10

Cash Flows Statements - Coming Soon

* In Million of Egypt Pound

Reminder: The financial information on this website is delayed information that are originates from certified data providers in the financial markets, who retain the rights and intellectual property of this data, absolving ADMN of any responsibility.